Journal Mobile Options
Table of Contents
Vol. 208, No. 1, 2004
Issue release date: 2004
Section title: Pharmacology and Treatment
Dermatology 2004;208:43–48
(DOI:10.1159/000075045)

Interferon Alpha as Adjuvant Postsurgical Treatment of Melanoma: A Meta-Analysis

Pirard D. · Heenen M. · Melot C. · Vereecken P.
aDepartment of Dermatology and bIntensive Care, Erasme Hospital, Brussels, Belgium

Do you have an account?

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

Register and profit from personalized services (MyKarger) Login Information

Please create your User ID & Password





Contact Information









I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger (new!)
  • Unrestricted printing, no saving restrictions for personal use
  • Reduced rates with a PPV account
read more

Direct: USD 38.00
Account: USD 26.50

Select

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restriction apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Automatic perpetual access to all articles of the subscribed year(s)
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select


Article / Publication Details

First-Page Preview
Abstract of Pharmacology and Treatment

Received: 4/1/2003
Accepted: 7/29/2003
Published online: 2/3/2004

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM

Abstract

Background: The literature on the benefit of α-interferon (IFN-α) as adjuvant postsurgical treatment of melanoma reports discordant results. Objective: With the published data so far, we performed a meta-analysis in order to evaluate the effect of IFN-α on the relapse rate (RR) and the overall survival (OS). Methods: Published randomised trials were identified by Medline search. Stage IV melanoma was not considered. Results: Nine published studies were included, with a total of 2,880 patients. Both the per protocol and the intention-to-treat analysis show that IFN-α significantly decreased the RR (OR = 0.74; 95% CI = 0.64–0.86). Subgroup analyses show that, for all stages, high and low doses decreased the RR (OR = 0.71, 95% CI = 0.54–0.92, and OR = 0.76, 95% CI = 0.63–0.91, respectively). No difference has been evidenced on OS. Conclusions: High and low doses of IFN-α significantly decrease the RR, but the OS does not seem to be improved.


Article / Publication Details

First-Page Preview
Abstract of Pharmacology and Treatment

Received: 4/1/2003
Accepted: 7/29/2003
Published online: 2/3/2004

Number of Print Pages: 6
Number of Figures: 2
Number of Tables: 1

ISSN: 1018-8665 (Print)
eISSN: 1421-9832 (Online)

For additional information: http://www.karger.com/DRM


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.